B. Tweedy, Ch. Browne
Tweedy, Browne Co All Funds (US)
Tweedy, Browne Co All Funds (US) Merck & Company Inc stake
total: 185
Tweedy, Browne Co All Funds (US) MRK trades
- Total transactions:
- 6
- New positions:
- 3
- Sold out:
- 3
- Held since:
- 2018 Q2
- Held for:
- 10 quarters
- Latest activity:
- 2020 Q4
According to 2026 Q2 report, Tweedy, Browne Co All Funds (US) doesn't hold any Merck & Company Inc (MRK) shares. To date, the estimated cost basis is nearly $60.8 for "buy" trades and estimated average "sell" price is $82.88. Tweedy, Browne Co All Funds (US) first purchased MRK in 2016 Q3, initially acquiring 3,306 shares. Tweedy, Browne Co All Funds (US) later completely sold out the position and invested in Merck & Company Inc again in 2018 Q2. Since the initial investment in Merck & Company Inc (MRK), Tweedy, Browne Co All Funds (US) has made 5 more transactions.
When did Tweedy, Browne Co All Funds (US) sell Merck & Company Inc (MRK)?
Tweedy, Browne Co All Funds (US) sold off the entire Merck & Company Inc (MRK) position in 2020 Q4.
When did Tweedy, Browne Co All Funds (US) buy Merck & Company Inc (MRK)?
Tweedy, Browne Co All Funds (US) first invested in Merck & Company Inc (MRK) in 2016 Q3 at the reported quarter-end price of $62.31 per share.
What's the cost basis of Tweedy, Browne Co All Funds (US)'s MRK stake?
The estimated cost basis for Merck & Company Inc (MRK) stake is around $60.80 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $60.80
- Weighted AVG sell price:
- $82.88
Tweedy, Browne Co All Funds (US)'s historical trades in Merck & Company Inc
6 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2020 Q4
|
0.00%
|
$82.88
|
-100% (-3,306)
|
|||
|
2018 Q2
|
0.01%
|
$60.80
|
new
|
|||
|
2017 Q4
|
0.00%
|
$64.13
|
-100% (-3,306)
|
|||
|
2017 Q1
|
0.01%
|
$63.52
|
new
|
|||
|
2016 Q4
|
0.00%
|
$62.31
|
-100% (-3,306)
|
|||
|
2016 Q3
|
0.01%
|
$62.31
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.